A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL, 4-ARM DOSE RANGING STUDY OF THE SAFETY AND EFFICACY OF NAL ER TABLETS FOR THE TREATMENT OF COUGH IN IDIOPATHIC PULMONARY FIBROSIS (IPF)
- Registry ID
- NAL03-202
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Study type
- INTERVENTIONAL
- Sponsor
- TREVI THERAPEUTICS INC
- Start date
- 2024-09-10
- Completion date
- 2025-03-27
- Last update
- 2023-08-21
Conditions
- PULMONARY FIBROSIS
- CHRONIC COUGH
Related clinical trials
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NALBUPHINE EXTENDED-RELEASE TABLETS FOR THE TREATMENT OF PARTICIPANTS WITH REFRACTORY CHRONIC COUGH
- A PHASE IIB STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF AZD8965 IN PARTICIPANTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) (ARGINAUT)
- A MULTINATIONAL, LONG-TERM, OPEN-LABEL EXTENSION STUDY OF SUBJECTS WHO HAVE PARTICIPATED IN AVALYN PHARMA STUDIES OF INHALED ANTIFIBROTIC AGENTS (AP-LTE-008 [SAIL])
- A PHASE 3, 24-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLELARM EFFICACY AND SAFETY STUDY WITH OPEN-LABEL EXTENSION OF BLU-5937 IN ADULT
PARTICIPANTS WITH REFRACTORY CHRONIC COUGH INCLUDING UNEXPLAINED CHRONIC
COUGH (CALM-2)
- A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE
EFFICACY, SAFETY, AND TOLERABILITY OF TAPLUCAINIUM INHALATION POWDER (NOC-110)
IN ADULTS WITH REFRACTORY OR UNEXPLAINED CHRONIC COUGH
- A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL EVALUATING THE SAFETY AND EFFICACY OF ENV-101 IN PATIENTS WITH LUNG FIBROSIS (WHISTLE-PF TRIAL)
View on source registry